Artificial intelligence (AI) has the potential to significantly reduce pharmaceutical R&D costs by streamlining drug discovery, optimizing clinical trials, and minimizing costly failures through data-driven predictions and effectiveness assessments. This potential was acknowledged by the pharmaceutical industry professionals in a survey* conducted by GlobalData, a leading data and analytics company.
The post AI Set to Improve Pharmaceutical R&D Productivity and Lower the Costs Says GlobalData appeared first on HPCwire.
